Invanz

Ertapenem, the active ingredient in Invanz, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous injection use. It provides broad‑spectrum bactericidal activity and is employed to treat serious bacterial infections, including intra‑abdominal, skin and soft‑tissue, respiratory, urinary and gynecologic infections in adult patients under medical supervision in hospital settings.

GNH USA supplies Invanz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, including tertiary care centers, specialty clinics and procurement agencies, and ensuring timely delivery across continents worldwide.

Invanz (ertapenem) is indicated for several serious bacterial infections affecting different organ systems.

Complicated intra‑abdominal infections: provides bactericidal coverage against Gram‑negative, Gram‑positive and anaerobic pathogens, facilitating clinical cure. Complicated skin and soft tissue infections: achieves rapid bacterial eradication in deep or extensive soft‑tissue disease. Community‑acquired pneumonia: delivers effective treatment against typical respiratory pathogens, improving patient outcomes. Urinary tract infections: offers broad activity against uropathogens, supporting resolution of complicated infections. Gynecologic infections: treats pelvic and postoperative infections by targeting the likely bacterial spectrum.

Ertapenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in some patients. - Diarrhea: loose stools that may be self‑limiting. - Headache: transient cranial discomfort. - Infusion site phlebitis: redness or pain at the injection site. - Rash: mild skin erythema. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Clostridioides difficile‑associated diarrhea: severe colitis requiring medical attention. - Seizures: particularly in patients with pre‑existing CNS disorders. - Acute renal impairment: sudden decline in kidney function. - Neutropenia: marked reduction in white blood cell count. - Thrombocytopenia: low platelet count leading to bleeding risk.

Prior to initiating ertapenem therapy, several precautionary measures should be considered to minimize risk. - Renal function: assess creatinine clearance and adjust dose in renal impairment. - Hepatic impairment: monitor liver function tests during treatment. - Allergy history: avoid use in patients with known carbapenem or β‑lactam hypersensitivity. - Pregnancy: safety not established; use only if potential benefit justifies risk. - Concomitant valproic acid: increased risk of seizures; consider alternative therapy. - Pediatric use: not approved for children; reserve for specific indications under specialist guidance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ertapenem can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: co‑administration may precipitate seizures. - Probenecid: may reduce renal clearance of ertapenem, increasing toxicity risk. - Live vaccines: concurrent use can diminish vaccine efficacy and increase infection risk.

Moderate Interactions (Monitor Closely): - Diuretics: potential for electrolyte imbalance; monitor serum levels. - Aminoglycosides: additive nephrotoxicity; assess renal function regularly. - Anticoagulants (warfarin): may alter INR; check coagulation parameters. - Oral contraceptives: reduced hormonal efficacy; advise additional contraceptive measures. - NSAIDs: possible renal function impact; monitor kidney parameters.